ProQR (PRQR) AI Stock Analysis

• Market Cap: $167.29M
• Dividend Yield: N/A
• Average Volume (3M): 625.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: 82.38%
• EPS Growth: 3.63%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 105,212,524
• 10 Day Avg. Volume: 689,010
• 30 Day Avg. Volume: 625,465
• PEG Ratio: 0.22
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.40
• Price Target Upside: 383.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

ProQR's overall stock score is primarily affected by its financial performance, where revenue growth is overshadowed by persistent losses and cash flow problems. The technical analysis indicates potential short-term bullish momentum, but the valuation remains a concern due to the negative P/E ratio. Improvements in profitability and cash flow are critical for enhancing the stock's attractiveness.

Positive Factors

Clinical Development

The next-generation AX-0810 has shown a 5.5-fold increase in potency over earlier NTCP EON iterations, along with improved stability in vitro and no evidence of hepatotoxicity or immunostimulatory effects, which indicates a favorable pharmacokinetic, pharmacodynamic, and safety profile.

Financial Position

PRQR ended with $156M in cash, which management estimates is sufficient runway into mid-2027.

Partnerships and Collaborations

ProQR continues to execute on its partnership with Lilly, which includes potential data updates and milestone income.

Negative Factors

Market Challenges

The continued stock decline following a mid-October spike suggests recent market challenges for PRQR.

Market Valuation

The pipeline is valued at more than $50 million, with shares trading nearly at cash, indicating potential undervaluation.

Pipeline Risks

Catalysts are expected to return after a multi-year pipeline reset following the LCA10 failure, with key developments anticipated in the coming years.

ProQR Business Overview & Revenue Model

Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

How the Company Makes Money

ProQR Therapeutics generates revenue through a combination of strategic collaborations, partnerships, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments based on the achievement of certain development or regulatory goals, and royalties on future sales of any successfully developed products. Additionally, ProQR may receive funding from government grants and research institutions to support its innovative RNA-based drug development programs. The company's focus on addressing unmet medical needs in rare genetic disorders positions it to potentially benefit from orphan drug designations, which can provide market exclusivity and other financial incentives.

ProQR Financial Statement Overview

Summary

ProQR is experiencing revenue growth, which is promising for future operations. Nevertheless, persistent losses and negative cash flows highlight financial challenges. The company's balance sheet remains relatively stable, supported by strong cash reserves, but profitability and cash flow improvements are needed for long-term sustainability.

Income Statement

ProQR's revenue has shown significant growth from 2023 to 2024, indicating positive development in sales. However, the company continues to face substantial net losses and negative EBIT and EBITDA margins, which suggests ongoing operational challenges and profitability issues.

Balance Sheet

The company's balance sheet reflects a moderate debt-to-equity ratio, indicating manageable leverage levels. However, the equity ratio has decreased, implying a reduction in the company's financial stability. The consistent increase in cash and short-term investments is a positive sign, enhancing liquidity.

Cash Flow

Free cash flow has deteriorated significantly in 2024 compared to 2023, raising concerns about cash generation. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to net losses. The company benefits from strong financing activities, boosting cash reserves.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
18.91M	6.51M	4.04M	1.35M	0.00
	Gross Profit
18.91M	6.38M	1.56M	1.35M	-2.19M
	EBIT
-30.47M	-31.86M	-64.72M	-57.19M	-42.37M
	EBITDA
-24.12M	-24.10M	-56.46M	-54.95M	-136.56M
	Net Income Common Stockholders
-27.76M	-28.12M	-64.89M	-61.68M	-46.61M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
149.41M	118.92M	94.78M	187.52M	75.84M
	Total Assets
167.96M	137.88M	171.32M	209.58M	98.73M
	Total Debt
17.22M	19.73M	21.97M	60.37M	34.28M
	Net Debt
-132.19M	-99.19M	-72.80M	-127.15M	-41.56M
	Total Liabilities
79.40M	96.49M	106.21M	96.35M	42.18M
	Stockholders Equity
88.56M	41.39M	65.50M	113.83M	57.09M
Cash Flow		Free Cash Flow
-37.81M	20.18M	-69.22M	-26.50M	-47.98M
	Operating Cash Flow
-36.39M	21.55M	-68.51M	-26.01M	-47.06M
	Investing Cash Flow
-4.07M	4.28M	-702.00K	-425.00K	-924.00K
	Financing Cash Flow
70.28M	-2.27M	-30.89M	136.83M	14.50M

ProQR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.53
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Negative. The current price of 1.53 is above the 20-day moving average (MA) of 1.52, above the 50-day MA of 1.53, and below the 200-day MA of 2.31, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 49.25 is Neutral, neither overbought nor oversold. The STOCH value of 19.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRQR.

ProQR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
CGEN	52 Neutral	$123.44M	87.50	-23.63%	―	-16.72%	26.35%
RGLS	52 Neutral	$544.87M	―	-53.82%	―	―	44.85%
TNXP	50 Neutral	$131.99M	―	-91.44%	―	-2.04%	-478.87%
PRQR	49 Neutral	$167.29M	―	-52.64%	―	82.38%	3.63%
SLN	49 Neutral	$180.89M	―	-99.23%	―	-40.10%	-16.60%
SEER	47 Neutral	$112.99M	―	-23.91%	―	-13.92%	-2.86%